BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives $381.46 Consensus PT from Brokerages

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) has earned a consensus rating of “Moderate Buy” from the fifteen brokerages that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and thirteen have issued a buy rating on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $381.4615.

A number of brokerages have recently commented on ONC. Citigroup raised their target price on shares of BeOne Medicines from $399.00 to $405.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Weiss Ratings restated a “sell (d-)” rating on shares of BeOne Medicines in a report on Wednesday, January 21st. Jefferies Financial Group reiterated a “buy” rating and issued a $420.00 target price on shares of BeOne Medicines in a report on Monday, November 17th. Morgan Stanley restated an “overweight” rating and set a $405.00 price target on shares of BeOne Medicines in a research note on Thursday, January 8th. Finally, Royal Bank Of Canada restated an “outperform” rating on shares of BeOne Medicines in a report on Wednesday, December 17th.

Insider Activity

In other news, SVP Chan Henry Lee sold 1,660 shares of the company’s stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $349.52, for a total value of $580,203.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO John Oyler sold 24,369 shares of BeOne Medicines stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $302.87, for a total transaction of $7,380,639.03. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 105,283 shares of company stock worth $32,463,041. 6.62% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On BeOne Medicines

Several institutional investors and hedge funds have recently added to or reduced their stakes in ONC. EFG International AG purchased a new stake in shares of BeOne Medicines during the fourth quarter valued at about $25,000. Anchor Investment Management LLC bought a new position in shares of BeOne Medicines during the 2nd quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd purchased a new stake in BeOne Medicines during the second quarter valued at approximately $28,000. Leonteq Securities AG acquired a new stake in BeOne Medicines in the fourth quarter valued at approximately $35,000. Finally, Daiwa Securities Group Inc. purchased a new position in BeOne Medicines in the second quarter worth $35,000. Hedge funds and other institutional investors own 48.55% of the company’s stock.

BeOne Medicines Trading Up 2.2%

ONC stock opened at $362.14 on Wednesday. BeOne Medicines has a 12 month low of $196.45 and a 12 month high of $385.22. The firm’s 50-day moving average is $333.08 and its 200 day moving average is $329.04. The company has a market capitalization of $39.71 billion, a PE ratio of 710.08 and a beta of 0.52. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.39 and a quick ratio of 2.17.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.